IGC Pharma Secures North American Composition Protection for IGC-AD1 as Phase 2 CALMA Enrollment AdvancesAccesswire • 02/17/26
IGC Pharma Expands Phase 2 CALMA Trial into Colombia's Premier Alzheimer's Research CenterAccesswire • 02/09/26
IGC Pharma Reaches 70% Enrollment in Phase 2 CALMA Trial Evaluating IGC-AD1 for Alzheimer's AgitationAccesswire • 02/02/26
IGC Pharma Expands Phase 2 CALMA Trial with New Clinical Trial Site at Integrative Clinical Trials in New YorkAccesswire • 01/22/26
IGC Pharma Expands Phase 2 CALMA Trial with New Clinical Site at Dominion Medical Associates, a Lightship Network Site, in Richmond, VirginiaAccesswire • 01/12/26
IGC Pharma Aligns Fiscal Year with Calendar Year to Enhance U.S. Investor Transparency and ComparabilityAccesswire • 01/06/26
IGC Pharma Secures New U.S. Patent as Pharmaceutical Cannabinoids Gain Regulatory MomentumAccesswire • 12/19/25
IGC Pharma Positions as a Singular Beneficiary of Emerging Federal Momentum Toward Schedule III Cannabinoid MedicinesAccesswire • 12/15/25
IGC Pharma Announces Coverage Report by Ascendiant Capital Markets about the "Reports Q2 results. We believe more positive clinical data and progress in 2025/26 to be strong catalysts for stock.Accesswire • 12/10/25
IGC Pharma Reports 65% Patient Enrollment Milestone in Phase 2 CALMA Alzheimer's Agitation TrialAccesswire • 12/09/25
IGC Pharma Announces Publication of Landmark Caregiver Book on Alzheimer's DiseaseAccesswire • 12/02/25
IGC Pharma Leverages MINT-AD to Identify Socioeconomic Risk Factors Driving Alzheimer's and Aging TrendsAccesswire • 11/25/25
IGC Pharma Reports Accelerated Q2 Progress and Strengthened Financial Focus: CALMA Trial Passes 50% Enrollment Milestone, Strategic Divestiture Optimizes CapitalAccesswire • 11/17/25
USPTO Grants IGC Pharma Patent Covering IGC-AD1 for Novel Composition Targeting Alzheimer's Disease and Central Nervous System DisordersAccesswire • 11/13/25
IGC Pharma to Host Mid-Year Fiscal 2026 Shareholder Update Call on November 17, 2025Accesswire • 11/10/25
All You Need to Know About IGC Pharma, Inc. (IGC) Rating Upgrade to Strong BuyZacks Investment Research • 10/24/25
IGC Pharma Advances to Semi-Finals in the Alzheimer's Insights AI Prize with "AHA: Agentic Harmonization Assistant"Accesswire • 10/22/25
IGC Pharma Expands Phase 2 CALMA Clinical Trial to University of South Florida's Department of Psychiatry and Behavioral NeurosciencesAccesswire • 10/14/25